LETROZOLE DEXCEL

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

LETROZOLE

Available from:

DEXCEL LTD, ISRAEL

ATC code:

L02BG04

Pharmaceutical form:

FILM COATED TABLETS

Composition:

LETROZOLE 2.5 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

HAUPT PHARMA MUNSTER GmbH, GERMANY

Therapeutic group:

LETROZOLE

Therapeutic area:

LETROZOLE

Therapeutic indications:

Letrozole - Dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole - Dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Authorization date:

2016-02-29